https://www.selleckchem.com/pr....oducts/gf109203x.htm
ation and of tobacco dependence through the relief of nicotine withdrawal symptoms, including cravings. Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic Tlymphocyte-associated protein4 (CTLA-4) drug tremelimumab. The aim of this review was to systematically identify and revise the current scientific literature investigating the combin
Like
Comment
Share
